Sunobinop
Source: Wikipedia, the free encyclopedia.
Chemical compound
Clinical data | |
---|---|
Other names | IMB-115 |
Drug class | Nociceptin receptor agonist |
Identifiers | |
| |
JSmol) | |
| |
|
Sunobinop (developmental code name IMB-115) is a nociceptin receptor partial agonist and opioid receptor pan-antagonist.[1] As of March 2022, it is under investigation for the treatment of insomnia,[2] fibromyalgia, and overactive bladder.[1][3]
See also
References
- ^ a b "Sunobinop - Shionogi/Imbrium Therapeutics". AdisInsight. Springer Nature Switzerland AG.
- PMID 37883189.
- ^ WO application 2018020418, Harris SC, Kapil RP, Kyle DJ, Whiteside G, "Treatment and prevention of sleep disorders", published 2018-02-01, assigned to Purdue Pharma L.P.